|
Corporate Presentation |
|
Seladelpar for the Treatment of Primary Biliary Cholangitis: Experience with 25 Cirrhotic Patients |
|
Treatment of Patients with Primary Biliary Cholangitis with Seladelpar for 52 Weeks Improves Predicted Transplant-free Survival |
|
Comparison of Seladelpar and Combinations with Liraglutide or Selonsertib for Improvement of Fibrosis and NASH in a Diet-Induced and Biopsy-Confirmed Mouse Model of NASH |
|
EASL 2019 Pharmacokinetics Safety and Tolerability of Seladelpar in Subjects with Hepatic Impairment |
